V. V. Rafalsky

651 total citations · 1 hit paper
13 papers, 418 citations indexed

About

V. V. Rafalsky is a scholar working on Epidemiology, Infectious Diseases and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, V. V. Rafalsky has authored 13 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 3 papers in Infectious Diseases and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in V. V. Rafalsky's work include Urinary Tract Infections Management (3 papers), Pediatric Urology and Nephrology Studies (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (2 papers). V. V. Rafalsky is often cited by papers focused on Urinary Tract Infections Management (3 papers), Pediatric Urology and Nephrology Studies (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (2 papers). V. V. Rafalsky collaborates with scholars based in Russia, Australia and Italy. V. V. Rafalsky's co-authors include Oliver Lenz, Antonio Craxı̀, Rekha Sinha, Gregory J. Dore, Ronald Kalmeijer, Michael Fried, Sivi Ouwerkerk‐Mahadevan, Maria Beumont‐Mauviel, Jane Scott and Ira M. Jacobson and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Cochrane Database of Systematic Reviews.

In The Last Decade

V. V. Rafalsky

10 papers receiving 403 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Gregory J. Dore et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. V. Rafalsky Russia	6	342	327	91	40	20	13	418
Stephen Shafran Canada	6	231 0.7×	95 0.3×	199 2.2×	8 0.2×	18 0.9×	15	315
G.B. Gaeta Italy	14	329 1.0×	355 1.1×	46 0.5×	55 1.4×	10 0.5×	44	505
Reham Soliman Egypt	15	517 1.5×	533 1.6×	71 0.8×	25 0.6×	9 0.5×	49	651
Inmaculada Jiménez-Nàcher Spain	9	235 0.7×	265 0.8×	246 2.7×	19 0.5×	45 2.3×	19	471
Laura Benítez‐Gutiérrez Spain	13	278 0.8×	310 0.9×	148 1.6×	21 0.5×	5 0.3×	20	414
S. Gordon United States	9	221 0.6×	213 0.7×	59 0.6×	16 0.4×	8 0.4×	14	295
Donghan Luo United States	11	256 0.7×	277 0.8×	177 1.9×	26 0.7×	7 0.3×	38	424
Erica D. Greanya Canada	12	200 0.6×	171 0.5×	99 1.1×	10 0.3×	35 1.8×	20	361
Evelyn Crewe Australia	12	559 1.6×	527 1.6×	52 0.6×	21 0.5×	7 0.3×	18	615
Peter Varunok United States	4	484 1.4×	537 1.6×	149 1.6×	37 0.9×	4 0.2×	4	557

Countries citing papers authored by V. V. Rafalsky

Since Specialization

Citations

This map shows the geographic impact of V. V. Rafalsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. V. Rafalsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. V. Rafalsky more than expected).

Fields of papers citing papers by V. V. Rafalsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. V. Rafalsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. V. Rafalsky. The network helps show where V. V. Rafalsky may publish in the future.

Co-authorship network of co-authors of V. V. Rafalsky

This figure shows the co-authorship network connecting the top 25 collaborators of V. V. Rafalsky. A scholar is included among the top collaborators of V. V. Rafalsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. V. Rafalsky. V. V. Rafalsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Rafalsky, V. V., et al.. (2023). Treatment of asthenic syndrome in young and middleaged patients with subjective cognitive impairment: observational non-interventional program. 38(3). 24–29.

Rafalsky, V. V., et al.. (2023). Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine. SHILAP Revista de lepidopterología. 4–12. 1 indexed citations

Жданов, К. В., et al.. (2021). The use of antiviral drug based on technologically processed antibodies to interferon-γ, CD4 receptor and histamine in the treatment of influenza in adults: results of a multicenter open-label randomized comparative trial with oseltamivir. Infekcionnye bolezni. 19(1). 39–57. 1 indexed citations

Rafalsky, V. V., et al.. (2020). Prospects for Raman spectroscopy in cardiology. CARDIOVASCULAR THERAPY AND PREVENTION. 19(1). 70–77. 2 indexed citations

Rafalsky, V. V., et al.. (2020). Prospects for Raman spectroscopy in cardiology. SHILAP Revista de lepidopterología. 19(1). 70–77. 8 indexed citations

Rafalsky, V. V., et al.. (2018). EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION. SHILAP Revista de lepidopterología. 6(2). 30–37. 6 indexed citations

Rafalsky, V. V.. (2018). Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation. SHILAP Revista de lepidopterología. 6(3). 50–56. 6 indexed citations

Rafalsky, V. V., et al.. (2017). LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS. CARDIOVASCULAR THERAPY AND PREVENTION. 16(4). 68–75.

Rafalsky, V. V., et al.. (2016). Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. International Journal of Infectious Diseases. 51. 47–55. 17 indexed citations

10.

Jacobson, Ira M., Gregory J. Dore, Graham R. Foster, et al.. (2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 384(9941). 403–413. 333 indexed citations breakdown →

11.

Chang, Ting‐Tsung, Ching‐Lung Lai, Patricia Desmond, et al.. (2007). Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901. 2 indexed citations

12.

Rafalsky, V. V., et al.. (2006). Quinolones for uncomplicated acute cystitis in women. Cochrane Database of Systematic Reviews. CD003597–CD003597. 41 indexed citations

13.

Rafalsky, V. V., et al.. (1970). Clinical pharmacology of acetylsalicylic acid as an anti-thrombotic agent. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact